查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1868331

異位性皮膚炎市場：2025-2032年全球預測（按產品、給藥途徑、嚴重程度、患者族群和通路）

Atopic Dermatitis Market by Product, Mode Of Administration, Severity Level, Patient Demographics, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，異位性皮膚炎市場規模將達到 334.4 億美元，複合年成長率為 6.09%。

關鍵市場統計數據
基準年 2024 208.3億美元
預計年份：2025年 220.2億美元
預測年份 2032 334.4億美元
複合年成長率 (%) 6.09%

本文簡要概述了相關人員在異位性皮膚炎管理方面正在發生的臨床、治療和服務層面的演變趨勢。

異位性皮膚炎的治療策略正從以症狀管理為主逐漸轉向以治療創新、整合式診療路徑和以病人為中心的醫療服務模式為重點。本執行摘要探討了影響臨床實踐、產品開發和分銷策略的核心趨勢，重點介紹了生物製藥和小分子藥物的相互作用、基於器械的干涉措施以及數位醫療在疾病長期管理中日益重要的作用。

標靶治療、數位化醫療模式和循證支付決策的創新如何重新定義異位性皮膚炎的治療路徑

近年來，治療方法、給藥系統和醫療體系組織這三大領域的同步創新帶來了變革性的變化，正在重塑人們對異位性皮膚炎治療的預期。精準標靶生物製藥和JAK抑制劑為長期使用的外用藥物提供了替代治療流程；同時，照光治療技術的進步和照光治療通訊協定的改進也重新激發了人們對針對特定患者群體的器械主導治療的興趣。

評估近期關稅政策變化如何重塑籌資策略、供應鏈韌性及其對異位性皮膚炎生態系統採購優先事項的影響

近期一系列關稅政策的累積影響（這些政策將持續到2025年）為異位性皮膚炎產品相關相關人員的供應鏈規劃、採購和成本管理帶來了新的複雜性。關稅調整影響進口的活性藥物原料藥、專用醫療設備組件和某些成品，促使製造商重新評估籌資策略，並考慮將生產外包或建立多元化的供應商網路，以降低貿易政策波動帶來的風險。

基於深度細分的洞察，揭示了產品分類、給藥途徑、病情嚴重程度、患者人口統計特徵和通路如何顯著影響治療方案的採納和獲取。

深入的市場細分闡明了治療方案、給藥方式、疾病嚴重程度、患者族群特徵和分銷管道如何相互交織，共同影響臨床和商業性結果。從產品觀點來看，此領域可分為兩大類：照光治療和藥物治療。照光治療包括準分子雷射療法、PUVA療法和UVB療法，每種療法都有不同的療效和操作特點，適用於特定的病變類型和醫療環境。藥物治療涵蓋了從傳統抗生素、抗病毒藥物、抗真菌藥物、抗組織胺和皮質類固醇到新型藥物，例如Janus激酶抑製劑和單株抗體，以及局部免疫調節劑，例如Pimecrolimus和Tacrolimus。這些產品特性導致了處方實踐的多樣性，以及支付方和臨床醫生對證據的不同要求。

區域醫療保健系統、監管環境和支付方策略如何塑造全球市場中治療方案採納的不同路徑

區域趨勢對臨床實踐、法規結構和商業策略有顯著影響，必須從地緣政治和醫療保健系統的角度進行分析。在美洲，成熟的專科醫療網路、競爭激烈的生物製藥市場以及完善的支付系統，促使人們更加關注療效比較證據和患者准入項目。這些趨勢重視明確的差異化和可靠的長期安全性數據，同時也為價格談判和事先核准流程帶來了壓力。

競爭格局概述：製藥創新者、醫療設備製造商和數位醫療參與企業如何重塑商業化和合作模式

異位性皮膚炎領域的競爭格局由成熟的製藥公司、皮膚病專科公司、早期生物技術創新者、醫療設備製造商以及新興的數位療法提供者組成。大型製藥公司持續投資於現有治療領域的生命週期管理，同時透過後期臨床計畫推動下一代生物製劑和口服小分子藥物的研發。同時，規模較小的生技公司則致力於作用機制和特定適應症的創新，並經常與大型企業合作，擴大生產和分銷規模。

採取切實有效、影響深遠的策略行動，整合臨床證據、市場進入途徑和營運韌性，以推動持續推廣應用。

產業領導者應優先考慮整合臨床開發、市場進入和真實世界證據產生的策略。在商業生命週期的早期階段投資於務實性試驗和縱向安全性研究，將有助於與支付者進行談判，並促進臨床指南的採納。同樣，建立由支付方、臨床醫生和患者代表組成的多方相關利益者諮詢委員會，可以簡化證據要求，並加快推廣進程。

本報告的調查方法採用了穩健的調查方法，結合了文獻綜合、相關人員訪談和跨細分分析，以確保研究結果的透明性和可重複性。

本報告的研究綜合了已發表的科學文獻、監管文件、臨床試驗註冊資訊以及對臨床醫生、支付方和行業高管的定性訪談。研究採用數據三角驗證法來檢驗主題性發現，結契約行評審研究、專家臨床指南和醫療系統採購報告的證據，從而建構了治療方法採納和獲取趨勢的多方面觀點。

一份簡明扼要、綜合摘要，旨在最大限度地提高治療效果，重點強調臨床證據整合、營運韌性和以患者為中心的就醫途徑。

總之，異位性皮膚炎的治療正處於一個關鍵的轉折點，治療創新、不斷發展的醫療服務模式以及不斷變化的政策環境相互交織，既帶來了機遇，也帶來了挑戰。新的治療方法和輔助技術有望顯著改善患者的治療效果，但相關人員必須應對複雜的報銷流程、供應鏈的不確定性以及各地不同的要求。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • Janus激酶抑制劑作為兒童異位性皮膚炎一線口服療法的應用日益增多
  • 整合數位健康平台，用於遠端監測和管理異位性皮膚炎急性發作
  • 消費者對潔淨標示、無香精的敏感特應性皮膚炎外用潤膚劑的需求激增
  • 不斷增加的真實世界證據研究表明，生物製藥治療異位性皮膚炎具有長期安全性。
  • 增加針對慢性異位性皮膚炎發炎的微生物組調節療法的投資
  • 遠距皮膚病學網路的出現改善了農村地區異位性皮膚炎患者獲得專科醫生服務的機會。
  • 監理核准新型IL-4和IL-13受體拮抗劑用於治療皮膚炎，協助其進入全球市場
  • 製藥公司和化妝品公司合作開發用於治療異位性皮膚炎的混合型護膚方案
  • 開發穿戴式感測器技術，用於持續監測皮膚炎管理中的皮膚屏障功能

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 異位性皮膚炎產品市場

  • 照光治療
    • 準分子雷射療法
    • PUVA療法
    • UVB療法
  • 藥物治療
    • 抗生素、抗病毒藥物或抗黴菌藥物
    • 抗組織胺藥
    • 皮質類固醇
    • Janus激酶（JAK）抑制劑
    • 單株抗體
    • Pimecrolimus或Tacrolimus

9. 依給藥途徑分類的異位性皮膚炎市場

  • 口服
    • 膠囊
    • 藥片
  • 腸外給藥
    • 肌肉內注射
    • 靜脈注射
  • 局部用藥
    • 奶油
    • 洗劑
    • 軟膏

第10章 依嚴重程度分類的異位性皮膚炎市場

  • 輕度異位性皮膚炎
  • 中度異位性皮膚炎
  • 重度異位性皮膚炎

第11章 按患者群體分類的異位性皮膚炎市場

  • 成年患者
  • 兒科患者

第12章 按分銷管道分類的異位性皮膚炎市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 各地區性異位性皮膚炎市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 依組別分類的異位性皮膚炎市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國異位性皮膚炎市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Bausch Health Companies Inc.
    • Biofrontera AG
    • Bristol-Myers Squibb Company
    • Chugai Pharmaceutical Co., Ltd.
    • Daavlin Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Galderma Holding SA
    • GlaxoSmithKline PLC
    • Incyte Corporation
    • Johnson & Johnson Services Inc.
    • LEO Pharma A/S
    • Maruho Co., Ltd
    • Novartis AG
    • Perrigo Company PLC
    • Pfizer, Inc.
    • Regeneron Pharmaceuticals, Inc
    • Sanofi SA
    • Solarc Systems Inc.
    • Teva Pharmaceutical Industries Ltd.
    • UCB SA
    • Viatris Inc.
Product Code: MRR-FE70EC183B6D

The Atopic Dermatitis Market is projected to grow by USD 33.44 billion at a CAGR of 6.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 20.83 billion
Estimated Year [2025] USD 22.02 billion
Forecast Year [2032] USD 33.44 billion
CAGR (%) 6.09%

A concise orientation to the evolving clinical, therapeutic, and service-level dynamics reshaping atopic dermatitis management across stakeholders

Atopic dermatitis continues to evolve from a primarily symptom-managed condition to a focal point for therapeutic innovation, integrated care pathways, and patient-centered service models. This executive summary introduces the core dynamics shaping clinical practice, product development, and distribution strategies, emphasizing the interplay between biologic and small-molecule therapeutics, device-based interventions, and the rising role of digital health in long-term disease management.

The introduction sets the stage by highlighting how clinical heterogeneity and patient demographics drive differentiated care needs. It explains the rationale for examining discrete therapy classes and delivery modes alongside severity tiers and distribution mechanisms to provide a holistic perspective. By framing the topic in terms of unmet clinical needs, reimbursement complexity, and evolving provider behavior, this section establishes the analytical lens used across the report and primes readers for detailed insights on market structure, stakeholder incentives, and adoption barriers.

How innovations in targeted therapies, digital care models, and evidence-driven payer decision-making are redefining atopic dermatitis treatment pathways

Recent years have witnessed transformative shifts that are recalibrating expectations for atopic dermatitis care, with innovation occurring concurrently across therapeutics, delivery systems, and health system organization. Precision-targeting biologics and JAK inhibitors have reframed treatment algorithms by offering alternatives to long-established topical agents, while advances in light-based therapies and refinement of phototherapy protocols have renewed interest in device-led interventions for particular patient segments.

Alongside therapeutic innovation, care delivery is being reshaped by greater emphasis on patient experience and chronic disease management. Telehealth and remote monitoring platforms have matured, enabling sustained adherence support and symptom tracking that influence therapy selection and escalation patterns. In parallel, health economics evidence is becoming central to payer decision-making; comparative effectiveness and real-world safety data are increasingly used to negotiate formularies and reimbursement criteria.

Moreover, cross-sector collaboration is accelerating translational pathways: partnerships among academic dermatology centers, biotech firms developing targeted agents, and medical device manufacturers are shortening time-to-clinic for combination approaches. Finally, heightened regulatory scrutiny on long-term safety and post-market surveillance has raised the bar for lifecycle strategies, prompting manufacturers to integrate evidence generation plans into early commercial preparations. These converging shifts necessitate adaptive strategies from clinicians, payers, and commercial teams alike.

Assessing how recent tariff developments have reshaped sourcing strategies, supply-chain resilience, and procurement priorities across the atopic dermatitis ecosystem

The cumulative impact of recent tariff policies enacted through 2025 has introduced new layers of complexity into supply chain planning, procurement, and cost management for stakeholders involved in atopic dermatitis products. Tariff adjustments have affected imported active pharmaceutical ingredients, specialized device components, and certain finished goods, which has encouraged manufacturers to reassess sourcing strategies and to explore nearshoring or diversified vendor networks to mitigate exposure to trade policy volatility.

As a consequence, manufacturers are increasingly prioritizing supply-chain resilience by negotiating longer-term contracts with strategic suppliers, qualifying multiple component sources, and investing in regional manufacturing capabilities where feasible. These measures are complemented by enhanced customs compliance functions and scenario planning that stress-test commercial and clinical timelines. For healthcare providers and payers, tariff-driven cost pressures have reinforced the importance of value-based procurement and therapeutic substitution policies that favor treatments with robust long-term outcomes data.

In addition, the tariff environment has catalyzed conversations about domestic capacity-building, particularly for high-value biologics and complex device assemblies. Stakeholders are weighing the trade-offs between near-term cost increases and the strategic benefits of reduced import dependency, faster replenishment cycles, and improved regulatory alignment. Ultimately, the policy backdrop underscores the necessity for integrated commercial and operational strategies that account for trade-related risks alongside clinical and market-access considerations.

Deep segmentation-driven insights that illuminate how product classes, administration routes, severity tiers, demographics, and channels materially affect treatment adoption and access

Insightful segmentation of the market clarifies how therapeutic choices, administration modalities, disease severity, patient age groups, and distribution channels intersect to shape clinical and commercial outcomes. When viewed through the product lens, the landscape is characterized by two broad categories: light therapy and medication. Light therapy encompasses excimer laser therapy, PUVA therapy, and UVB therapy, each offering distinct efficacy and operational profiles suitable for particular lesion patterns and care settings. Medication spans a range from conventional antibiotics, antivirals or antifungals, antihistamines, and corticosteroids to newer classes such as Janus kinase inhibitors and monoclonal antibodies, as well as topical immunomodulators like pimecrolimus or tacrolimus. These product distinctions drive heterogeneous prescribing practices and different evidence requirements for payers and clinicians.

Examining mode of administration reveals further granularity. Oral administration, including capsules and tablets, typically supports systemic management and is favored in more extensive disease or when topical adherence is poor. Parenteral administration, divided into intramuscular and intravenous routes, is associated with specialty clinic delivery, higher monitoring requirements, and different reimbursement pathways. Topical administration, delivered as creams, lotions, or ointments, remains central for maintenance therapy and for patients with localized disease, balancing tolerability with the need for sustained adherence and patient education.

Stratifying by severity level-mild, moderate, and severe-provides practical guidance for treatment sequencing and resource allocation. Mild disease often responds to topical therapies and basic self-management, while moderate cases may require escalation to systemic agents or phototherapy. Severe atopic dermatitis frequently necessitates specialty care, combination therapy approaches, and more intensive monitoring, which influences payer review processes and clinical referral patterns. Patient demographics also critically shape clinical pathways: adult patients often present with distinct comorbidity profiles and long-term treatment histories compared with pediatric patients, whose developmental considerations and caregiver dynamics inform adherence strategies and safety monitoring.

Distribution channel segmentation-hospital pharmacies, online pharmacies, and retail pharmacies-further determines access dynamics, formulary placement, and patient support program design. Hospital pharmacies and specialty infusion centers are pivotal for injectable biologics and intravenous therapies, while online pharmacies are increasingly important for chronic oral and topical therapies due to convenience and subscription models. Retail pharmacies remain fundamental for last-mile distribution and patient counseling, particularly for topical agents and over-the-counter adjuncts. Integrating these segmentation dimensions enables stakeholders to tailor clinical development, market-access tactics, and patient-support services to the nuanced needs of different subpopulations.

How regional healthcare systems, regulatory landscapes, and payer approaches are creating differentiated pathways for therapy adoption across global markets

Regional dynamics significantly influence clinical practice, regulatory frameworks, and commercial strategies, and must be analyzed through a geopolitical and health-system lens. In the Americas, established specialty care networks, a competitive biologics market, and sophisticated payer systems drive a focus on comparative effectiveness evidence and patient access programs. These dynamics reward clear differentiation and robust long-term safety data while also creating pressures around pricing negotiations and prior authorization processes.

Across Europe, Middle East & Africa, heterogeneity is pronounced: Western European markets tend to have mature HTA processes and well-defined reimbursement pathways that emphasize cost-effectiveness, while some Middle Eastern and African markets are working to expand specialty care infrastructure and access to advanced therapies. This region therefore necessitates adaptable market-access strategies that address variable procurement mechanisms and local capacity constraints. Importantly, real-world evidence and local pharmacoeconomic modeling are often decisive in securing access across diverse healthcare finance environments in this region.

In the Asia-Pacific region, growing healthcare investment, expanding dermatology specialty networks, and increasing patient awareness are accelerating uptake of innovative therapies, although market entry strategies must account for varying regulatory timelines and price sensitivity. Local manufacturing partnerships and tailored patient support initiatives can be effective in addressing affordability and distribution challenges. Across regions, cross-border collaboration on regulatory science and post-market surveillance is becoming more salient, and companies that can align regional evidence-generation plans with local stakeholder expectations are positioned to achieve more consistent adoption trajectories.

Competitive landscape overview showing how pharmaceutical innovators, device manufacturers, and digital health entrants are reshaping commercialization and partnership models

Competitive dynamics in atopic dermatitis are shaped by a mix of established pharmaceutical firms, specialty dermatology companies, early-stage biotech innovators, medical device manufacturers, and emerging digital therapeutics providers. Leading pharmaceutical players continue to invest in lifecycle management for established classes while simultaneously advancing next-generation biologics and oral small molecules through late-stage clinical programs. Meanwhile, smaller biotech firms contribute innovation in mechanism of action and niche indications, often partnering with larger organizations to scale manufacturing and distribution.

Device manufacturers are enhancing phototherapy platforms and developing outpatient-friendly delivery systems that expand access beyond tertiary centers. These product innovations are frequently supported by evidence-generation strategies that demonstrate comparative effectiveness, ease of use, and integration into clinic workflows. Digital health vendors and startups are complementing pharmacologic and device-based care with adherence tools, teledermatology services, and symptom-tracking platforms that increase sustained engagement and provide real-world data to support value claims.

Across the competitive landscape, companies that combine robust clinical data packages with agile market-access approaches and strong patient support ecosystems are most successful at securing durable uptake. Strategic partnerships, licensing agreements, and value-based contracting are increasingly common as firms seek to mitigate access barriers and align incentives with payers and providers. Overall, the market rewards a balance of scientific differentiation, operational excellence, and stakeholder-centric commercialization models.

Practical, high-impact strategic actions for leaders to align clinical evidence, market-access pathways, and operational resilience to drive sustainable adoption

Industry leaders should prioritize integrated strategies that align clinical development with market-access and real-world evidence generation. Investing in pragmatic trials and longitudinal safety studies early in the commercial lifecycle will support payer negotiations and clinical guideline inclusion. Similarly, establishing multi-stakeholder advisory boards that include payers, clinicians, and patient representatives can streamline evidence requirements and accelerate adoption pathways.

Operationally, building supply-chain redundancy and regional manufacturing options will reduce exposure to trade policy shocks and support faster time-to-market. Commercial teams should design tailored patient-support programs that reflect the needs of adult and pediatric populations, and leverage digital adherence tools to improve long-term outcomes. Finally, pursue flexible pricing and contracting mechanisms such as outcomes-based agreements where appropriate, and design value communication that speaks to both clinical endpoints and broader health system impacts, including resource utilization and patient quality of life.

Robust methodological approach combining literature synthesis, stakeholder interviews, and cross-segmentation analysis to ensure transparent, reproducible insights

The research underlying this report synthesizes publicly available scientific literature, regulatory filings, clinical trial registries, and primary qualitative interviews with clinicians, payers, and industry executives. Data triangulation was applied to validate thematic findings, combining evidence from peer-reviewed studies, specialty clinical guidelines, and health-system procurement reports to create a multi-dimensional view of therapeutic adoption and access dynamics.

Analytical methods included cross-segmentation mapping to identify interaction effects between product classes, modes of administration, severity levels, patient demographics, and distribution channels. Regional analysis drew on country-specific regulatory documents and payer guidance to contextualize adoption barriers. Qualitative insights were derived from semi-structured interviews designed to capture decision criteria used by clinicians and payers, while attention was paid to ensuring confidentiality and representativeness across stakeholder types. Throughout, the methodology emphasized transparency, reproducibility, and the integration of both clinical and commercial perspectives.

A concise synthesis of strategic imperatives emphasizing the integration of clinical evidence, operational resilience, and patient-centric access to maximize therapeutic impact

In conclusion, atopic dermatitis management stands at an inflection point where therapeutic innovation, evolving care delivery models, and shifting policy environments converge to create both opportunities and challenges. The emergent therapies and supportive technologies offer the potential to substantially improve patient outcomes, yet stakeholders must navigate complex reimbursement pathways, supply-chain uncertainties, and diverse regional requirements.

Successful organizations will be those that align scientific development with pragmatic evidence generation, invest in resilient operational models, and design patient-centric access programs. By integrating clinical, commercial, and policy considerations into a coherent strategy, decision-makers can better position their organizations to deliver meaningful improvements in care while maintaining sustainable business models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased adoption of Janus kinase inhibitors as first-line oral therapy in pediatric atopic dermatitis
  • 5.2. Integration of digital health platforms for remote monitoring and management of atopic dermatitis flares
  • 5.3. Surge in consumer demand for clean label, fragrance free topical emollients for sensitive atopic skin
  • 5.4. Expansion of real world evidence studies demonstrating long-term safety of biologic treatments in atopic dermatitis
  • 5.5. Growing investment in microbiome modulation therapies targeting chronic atopic dermatitis inflammation
  • 5.6. Emergence of teledermatology networks improving specialist access for rural atopic dermatitis patients
  • 5.7. Regulatory approvals driving global market entry of novel IL-4 and IL-13 receptor antagonists in dermatitis
  • 5.8. Collaboration between pharmaceutical and cosmetic companies to create hybrid therapeutic skincare solutions for atopic dermatitis
  • 5.9. Development of wearable sensor technology for continuous tracking of skin barrier integrity in dermatitis management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Atopic Dermatitis Market, by Product

  • 8.1. Light Therapy
    • 8.1.1. Excimer Laser Therapy
    • 8.1.2. PUVA Therapy
    • 8.1.3. UVB Therapy
  • 8.2. Medication
    • 8.2.1. Antibiotics, Antivirals or Antifungals
    • 8.2.2. Antihistamines
    • 8.2.3. Corticosteroid
    • 8.2.4. Janus Kinase (JAK) Inhibitors
    • 8.2.5. Monoclonal Antibodies
    • 8.2.6. Pimecrolimus or Tacrolimus

9. Atopic Dermatitis Market, by Mode Of Administration

  • 9.1. Oral Administration
    • 9.1.1. Capsules
    • 9.1.2. Tablets
  • 9.2. Parenteral Administration
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
  • 9.3. Topical Administration
    • 9.3.1. Cream
    • 9.3.2. Lotion
    • 9.3.3. Ointment

10. Atopic Dermatitis Market, by Severity Level

  • 10.1. Mild Atopic Dermatitis
  • 10.2. Moderate Atopic Dermatitis
  • 10.3. Severe Atopic Dermatitis

11. Atopic Dermatitis Market, by Patient Demographics

  • 11.1. Adult Patients
  • 11.2. Pediatric Patients

12. Atopic Dermatitis Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Atopic Dermatitis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Atopic Dermatitis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Atopic Dermatitis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Amgen Inc.
    • 16.3.3. AstraZeneca PLC
    • 16.3.4. Bausch Health Companies Inc.
    • 16.3.5. Biofrontera AG
    • 16.3.6. Bristol-Myers Squibb Company
    • 16.3.7. Chugai Pharmaceutical Co., Ltd.
    • 16.3.8. Daavlin Company
    • 16.3.9. Eli Lilly and Company
    • 16.3.10. F. Hoffmann-La Roche Ltd.
    • 16.3.11. Galderma Holding SA
    • 16.3.12. GlaxoSmithKline PLC
    • 16.3.13. Incyte Corporation
    • 16.3.14. Johnson & Johnson Services Inc.
    • 16.3.15. LEO Pharma A/S
    • 16.3.16. Maruho Co., Ltd
    • 16.3.17. Novartis AG
    • 16.3.18. Perrigo Company PLC
    • 16.3.19. Pfizer, Inc.
    • 16.3.20. Regeneron Pharmaceuticals, Inc
    • 16.3.21. Sanofi SA
    • 16.3.22. Solarc Systems Inc.
    • 16.3.23. Teva Pharmaceutical Industries Ltd.
    • 16.3.24. UCB S.A.
    • 16.3.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ATOPIC DERMATITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY EXCIMER LASER THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PUVA THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY UVB THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIBIOTICS, ANTIVIRALS OR ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY JANUS KINASE (JAK) INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PIMECROLIMUS OR TACROLIMUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY LOTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MILD ATOPIC DERMATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY MODERATE ATOPIC DERMATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY SEVERE ATOPIC DERMATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY SEVERITY LEVEL, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY LIGHT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST ATOPIC DERMATITIS MARKET SIZE, B